SkyePharma restructures debt as Flutiform makes progress
This article was originally published in Scrip
Executive Summary
SkyePharma's Japanese development and marketing Kyorin Pharmaceutical has submitted a new drug application (NDA) with the Japanese authorities for Flutiform (known in Japan as KRP-108) for asthma. The product announcement follows news that the UK-based firm has managed to restructure an earlier convertible bond in order to postpone demands on its cashflow. Although the move ramps up the amount it owes in the long term, the company says that the restructuring "significantly reduces liquidity demands over the next 24 months" and "better aligns repayment obligations with [SkyePharma's] cash generative potential." Flutiform was launched in Germany last week and in the UK on 25 September.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.